ArticleFrontiers in immunology2018
CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to Multivalent Antigens and Enhances Hemagglutination.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Structural insights into antibody-antibody interactions in sandwich ELISA: implications for assay development and performance.Analytical and bioanalytical chemistry · 2026Article
- Article
- Immunoglobulin constant regions provide stabilization to the paratope and enforce epitope specificity.The Journal of biological chemistry · 2024Article
- Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse Model.Pathogens (Basel, Switzerland) · 2023Article
- Targeting BMI-1 to deplete antibody-secreting cells in autoimmunity.Clinical & translational immunology · 2023Article
- High-valency Anti-CD99 Antibodies Toward the Treatment of T Cell Acute Lymphoblastic Leukemia.Journal of molecular biology · 2022Article
- A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model.Journal of nanobiotechnology · 2022Article
- Prolactin promotes proliferation of germinal center B cells, formation of plasma cells, and elevated levels of IgG3 anti-dsDNA autoantibodies.Frontiers in immunology · 2022Article
- Mouse IgG3 binding to macrophage-like cells is prevented by deglycosylation of the antibody or by Accutase treatment of the cells.Scientific reports · 2021Article
- Article
- Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.Cancer research · 2020Article
- Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma.Vaccines · 2020Article
- Monoclonal antibody-based therapies for bacterial infections.Current opinion in infectious diseases · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mouse IgG3 is highly protective against several life-threatening bacteria. This isotype is the only one among mouse IgGs that forms non-covalent oligomers, has increased functional affinity to polyvalent antigens, and efficiently agglutinates erythrocytes. IgG3 also triggers the complement cascade. The high efficacy of protection after passive immunization with IgG3 is correlated with the unique properties of this isotype. Although the features of IgG3 are well documented, their molecular basis remains elusive. Based on functional analyses of IgG1/IgG3 hybrid molecules with swapped constant domains, we identified IgG3-derived CH2 domain as a major determinant of antibody oligomerization and increased functional affinity to a multivalent antigen. The CH2 domain was also crucial for efficient hemagglutination triggered by IgG3 and was indispensable for complement cascade activation. This domain is glycosylated and atypically charged. A mutational analysis based on molecular models of CH2 domain charge distribution indicated that the functional affinity was influenced by the specific charge location. N-glycans were essential for CH2-dependent enhancement of hemagglutination and complement activation. Oligomerization was independent of CH2 charge and glycosylation. We also verified that known C1q-binding motifs are functional in mouse IgG3 but not in IgG1 framework. We generated for the first time a gain-of-function antibody with properties transferred from IgG3 into IgG1 by replacing the CH2 domain. Finding that the CH2 domain of IgG3 governs unique properties of this isotype is likely to open an avenue toward the generation of IgG3-inspired antibodies that will be protective against existing or emerging lethal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.